Abstract
Kerrie Westaway, Mary Cruickshank
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience
10.1067/mhj.2002.123112 · 2002
Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism
10.7326/0003-4819-140-3-200402030-00008 · 2004
The ineffectiveness of a non-weight based heparin regime in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome
10.1016/s1036-7314(00)70640-0 · 2000
Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
2004
Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin
10.7326/0003-4819-138-9-200305060-00008 · 2003
A standard heparin nomogram for the management of heparin therapy
10.1001/archinte.1991.00400020085018 · 1991
Appropriate use of heparin: empiric vs nomogram-based dosing
10.1001/archinte.1995.00430050104011 · 1995
The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram: a randomized control trial
10.7326/0003-4819-119-9-199311010-00002 · 1993
Weight-based heparin dosing: clinical response and resource utilization
datacite
Confidence 0%
10.1016/s0149-2918(98)80133-1 · 1998
In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone
10.1002/j.1875-9114.1998.tb03140.x · 1998
Effect of weight, sex, age, clinical diagnosis and thromboplastin reagent on steady-state intravenous heparin requirements
10.1001/archinte.1997.00440420100009 · 1997
Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time
1987
Prediction of blood volume and adiposity in man from body weight and cube of height
1956
Aging and heparin-related bleeding
10.1001/archinte.1996.00440080047006 · 1996
Different effects of heparin in males and females
1998
Pharmacokinetic optimisation of the treatment of deep vein thrombosis
10.2165/00003088-199732020-00005 · 1997
Hemorrhagic complications of intravenous heparin use
10.1016/s0002-9149(97)00309-3 · 1997
Anticoagulant, thrombolytic and antiplatelet drugs
1991
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial
10.1161/01.cir.93.5.870 · 1996
Heparin resistance induced by intravenous nitroglycerin: a word of caution when both drugs are used concomitantly
10.1001/archinte.1987.00370050053009 · 1987
Suboptimal monitoring and dosing of unfractionated heparin — to the editor [Editorial]
10.7326/0003-4819-140-7-200404060-00030 · 2004
Suboptimal monitoring and dosing of unfractionated heparin — in response [Editorial]
10.7326/0003-4819-140-7-200404060-00031 · 2004
A new regime for heparin use in acute coronary syndromes
10.1016/s0002-8703(99)70118-3 · 1999
The successful application of a heparin nomogram in a community hospital
10.1001/archinte.1995.00430190089012 · 1995
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
2002
Unresolved referenced work
1998
Optimal therapeutic level of heparin in patients with venous thrombosis
10.1001/archinte.1992.00400200027006 · 1992
New heparin dosing recommendations for patients with acute coronary syndromes
10.1016/s0002-9343(01)00715-x · 2001
A randomised, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease
10.1016/s0002-8703(99)70460-6 · 1999
No additional external references are available.